Waltham, MA–Nova Biomedical is happy to announce the launch of BioProfile FAST CDV, a high-throughput, totally automated viable cell density and viability analyzer able to producing ends in beneath 70 seconds with simply 100uL of pattern quantity. As well as, it performs all pattern dilutions internally, enabling cell tradition samples as much as 140e6 c/mL to be analyzed with none exterior pattern dilution. Cell tradition samples could be analyzed by way of the exterior 36- place load-and-go tray or by way of an revolutionary 96-well plate choice.
The software program is extraordinarily straightforward to make use of because of the built-in contact display show and intuitive icon-based navigation. All elements of the software program and networking capabilities are 21 CFR Half 11 compliant and have additionally been designed to satisfy the FDA’s new cybersecurity tips. The analyzer has a number of networking choices together with OPC and BioProfile Information Supervisor in addition to the flexibility to transmit photos.
FAST CDV makes use of trypan blue dye exclusion methodology for dedication of stay and useless cells and makes use of the business’s highest decision digital camera and optics coupled with probably the most superior algorithms to supply probably the most correct cell density and cell viability measurements. It additionally integrates seamlessly into current course of growth, pilot, and manufacturing laboratories the place the BioProfile FLEX2 is at the moment getting used. The FAST CDV algorithms align with the FLEX2 algorithms to guarantee correlation with the FLEX2 CDV module.
“We at Nova Biomedical are excited to launch the subsequent addition to the BioProfile platform with the FAST CDV Analyzer. Nova’s dedication to bringing superior expertise analyzers to our biotechnology worldwide clients is clear in our new analyzer. The FAST CDV is a big advance in automated cell density analyzers and breaks the boundaries of current applied sciences. It’ll allow even quicker analysis of cell traces and physicochemical parameter optimization, in the end bringing merchandise to market quicker,” mentioned Matt McRae, Biotechnology Gross sales Product Line Supervisor at Nova.
About Nova Biomedical Integrated in 1976 and primarily based in Waltham, MA, Nova Biomedical is a world chief within the growth and manufacturing of entire blood, point-of-care and significant care analyzers, in addition to devices for cell tradition monitoring within the biotechnology market. Nova makes use of biosensor expertise in merchandise starting from handheld meters for glucose self- and point-of-care testing to important care entire blood analyzers designed for stat measurement of over 22 analytes. Nova’s BioProfile line has pioneered complete cell tradition testing, offering over 20 important cell tradition checks for a broad vary of cell tradition functions. Nova employs over 1,400 individuals worldwide and has wholly owned subsidiaries situated in Benelux, Brazil, Canada France, Germany, Nice Britain, Italy, Japan Spain, Nova Biomedical, 200 Prospect Road, Waltham, MA 02454 U.S.A. Tel: 781-894-0800 www.novabiomedical.com and Switzerland. Licensed by the Worldwide Group for Standardization, Nova has manufacturing operations situated within the U.S. and Taiwan.